Trial Profile
A Randomised Open Label Exploratory, Safety and Tolerability Study With PP100-01 in Patients Treated With the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose (The POP Trial)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Acetylcysteine (Primary) ; Calmangafodipir (Primary)
- Indications Drug toxicity; Liver failure; Liver injury
- Focus Adverse reactions; Proof of concept
- Acronyms POP
- Sponsors Egetis Therapeutics; PledPharma
- 21 Aug 2019 According to a PledPharma media release, results of this study were recognized as one of the highlights at one of the worlds largest liver conferences, European Association of the Study of the Liver International Liver Congress (EASL ILC, April 2019).
- 15 Jul 2019 According to a PledPharma media release, data from this study was published in the Lancets EBioMedicine research journal.
- 15 Jul 2019 Results published in the PledPharma Media Release